<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Niti Aayog</title>
	<atom:link href="http://www.tapanray.in/tag/niti-aayog/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Blockchain: A Game Changer For Safe Medicines</title>
		<link>http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=blockchain-a-game-changer-for-safe-medicines</link>
		<comments>http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/#comments</comments>
		<pubDate>Mon, 09 Jul 2018 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[anti-counterfeit]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[combating]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9049</guid>
		<description><![CDATA[‘Your medicine box may have fake drugs’ was the March 18, 2018 headline of a popular pan Indian news daily. Just the year before, the 2017 report of the World Health Organization (WHO), also flagged that around 10.5 percent of all medicines in &#8230; <a href="http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing Pressure to Escalate Further?</title>
		<link>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-pressure-to-escalate-further</link>
		<comments>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/#comments</comments>
		<pubDate>Mon, 12 Feb 2018 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[Central Medical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalate]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Progressive India” report]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[“Healthy States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8849</guid>
		<description><![CDATA[On February 09, 2018, NITI Aayog released its “Healthy States, Progressive India” Report. The study ranked the States based on ‘health index’. Kerala, Punjab and Tamil Nadu featured as top three in terms of overall performance in 2015-16. However, the interstate variation &#8230; <a href="http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>At The Indian IPR Front: ‘Ground Control, There’s No Major Storm’</title>
		<link>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=at-the-indian-ipr-front-ground-control-theres-no-major-storm</link>
		<comments>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/#comments</comments>
		<pubDate>Mon, 05 Sep 2016 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[2016 Special 301 Report]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[4-5]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[G 20]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[September]]></category>
		<category><![CDATA[Sherpa]]></category>
		<category><![CDATA[storm]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7794</guid>
		<description><![CDATA[The incessant pressure of the developing countries on India, from 2005 to date, to include various restrictive conditions in the Indian Patents Act 2005, still continue. This demand spans across the inclusion of even those provisions, which many experts term &#8230; <a href="http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
